Evolving Approaches in the Management of Neuroendocrine Tumor-Associated Carcinoid Syndrome

Satya (Nanu) Das, MD, MSCI, provides an overview of the incidence rate and common symptoms of neuroendocrine tumors (NETs).

Rodney Pommier, MD, defines carcinoid syndrome and describes the process of diagnosis and clinical risk factors in patients.

Jerome Zacks, MD, explains carcinoid heart disease and its symptoms, and why it develops in some patients with NET-associated carcinoid syndrome.

Dr Satya (Nanu) Das discusses the typical management strategies for carcinoid syndrome-related symptoms, highlighting the use of somatostatin analogs.

Dr Rodney Pommier gives an overview of somatostatin analog-refractory carcinoid syndrome and the recommended approaches for management in patients.

A medical oncologist reviews the currently available, NCCN-approved treatments for somatostatin analog-refractory carcinoid syndrome.

Dr Pommier discusses key safety, efficacy, and quality of life data from the TELEPATH trial investigating the tryptophan hydroxylase inhibitor telotristat ethyl, while Dr Das comments on real-world data complements to the trial.

Dr Jerome Zacks explains strategies to prevent, treat, and manage carcinoid heart disease, and emphasizes the need for multidisciplinary approaches.

Experts comment on the current unmet needs for patients with neuroendocrine tumor-associated carcinoid syndrome.

Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.